Brand Intelligence Graphcompany
Company Overview
About Idexx Laboratories
IDEXX Laboratories is the global leader in veterinary diagnostics and information technology for companion animal healthcare, founded in 1983 by David Shaw in Westbrook, Maine, where it remains headquartered. The company trades on Nasdaq (IDXX) and reported $3.81 billion in revenues for FY2024, maintaining its dominant position in point-of-care veterinary diagnostics through an installed base of over 130,000 Catalyst chemistry analyzers, ProCyte hematology systems, and SNAP rapid assay devices deployed in veterinary clinics worldwide. CEO Jay Mazelsky has continued IDEXX's expansion into AI-powered diagnostics and digital pathology, building on over four decades of veterinary-specific product development.
Business Model & Competitive Advantage
IDEXX's competitive moat rests on several reinforcing advantages: a proprietary reagent consumable model that generates high-margin recurring revenue from its installed analyzer base, a global reference laboratory network providing specialized esoteric testing with 24-48 hour turnaround, and the VetConnect PLUS data platform that aggregates diagnostic results across in-clinic and reference lab testing for longitudinal patient monitoring. The 2023-2024 launch of inVue Dx—a digital cell imaging system using AI to automate differential cell counts from feline and canine blood samples—extends IDEXX's technical leadership in AI-assisted diagnostics. Veterinary clinic consolidation into corporate groups and private equity-backed networks is accelerating, creating larger multi-location customers that benefit from IDEXX's enterprise software and centralized ordering capabilities.
Competitive Landscape 2025–2026
In 2025-2026, IDEXX faces growing competition from Zoetis's Vetscan diagnostics line, Heska Corporation, and Antech Diagnostics (owned by Mars, Incorporated) in the veterinary diagnostics market. The pet humanization trend—driving increased annual wellness visits and diagnostic testing per pet—remained a secular tailwind through 2024-2025 even as the post-COVID pet boom moderated. International expansion, particularly in Europe and Asia Pacific where veterinary diagnostic penetration lags the United States, represents IDEXX's primary long-run growth opportunity. The company's pricing power, demonstrated through consistent price increases above inflation, reflects the diagnostic testing's small share of total veterinary visit costs and the clinical necessity of accurate diagnostics for treatment decisions.
The Idexx Laboratories Story
Founders
Recent Activity
View all →Company Timeline
Major milestones in Idexx Laboratories's journey
Leadership Team
Meet the leaders behind Idexx Laboratories
Jay Mazelsky (Jonathan J. Mazelsky)
Jay Mazelsky has served as President and Chief Executive Officer of IDEXX since June 2019. He leads the company's strategic direction, innovation initiatives, and global operations, driving IDEXX's market leadership in veterinary diagnostics and commitment to improving animal health worldwide through technological innovation and customer-focused solutions.
Brian P. McKeon
Brian McKeon has served as Executive Vice President, Chief Financial Officer, and Treasurer since 2014. He oversees all financial operations, strategic planning, capital allocation, investor relations, and M&A activities. McKeon plays a critical role in IDEXX's financial performance and sustainable growth strategy.
Michael P. Johnson
Michael Johnson joined IDEXX as Executive Vice President and Chief Human Resources Officer in January 2024. He leads talent acquisition, organizational development, compensation and benefits, employee engagement, and culture initiatives to support IDEXX's global workforce and foster an inclusive, high-performance environment.
Martin Smith
Martin Smith serves as Executive Vice President and Chief Technology Officer, leading IDEXX's innovation strategy, R&D initiatives, and product development across diagnostics, software, and laboratory services. He oversees the company's $219+ million annual R&D investment and breakthrough innovations like the inVue Dx analyzer and Cancer Dx testing.
Sharon E. Underberg
Sharon Underberg serves as Executive Vice President, General Counsel, and Corporate Secretary, overseeing legal affairs, compliance, corporate governance, risk management, and regulatory matters. She ensures IDEXX operates with the highest ethical standards and maintains compliance across global operations.
Ken Grady
Ken Grady has served as Senior Vice President and Chief Information Officer since 2016. He leads IDEXX's information technology strategy, cybersecurity, data management, and digital transformation initiatives, enabling the company's cloud-based diagnostic platforms and practice management software solutions.
Key Differentiators
Market Leader
Idexx Laboratories is recognized as a market leader in the Healthcare Tech sector, demonstrating strong industry presence and customer trust.
Enterprise Scale
With $3.81B in revenue, Idexx Laboratories operates at enterprise scale with proven market validation.
Frequently Asked Questions
Estimated Visibility Trend (Beta)
Simulated 8-week rolling score
Based on estimated brand signals. Historical tracking coming soon.
Similar Brands
GE HealthCare
GE HealthCare Technologies Inc. is a Chicago, Illinois-based medical technology and digital health company — publicly traded on the NASDAQ (NASDAQ: GEHC) as an S&P 500 Health Care component — designin
Incyte
Incyte Corporation is a Wilmington, Delaware-based biopharmaceutical company — publicly traded on the NASDAQ (NASDAQ: INCY) as an S&P 500 Health Care component — focused on oncology and inflammation,
Biogen
Biogen Inc. is a Cambridge, Massachusetts-based neuroscience biopharmaceutical company — publicly traded on NASDAQ (NASDAQ: BIIB) as an S&P 500 Health Care component — researching, developing, and com
Danaher Corporation
Danaher Corporation is a Washington, D.C.-based global science and technology company — publicly traded on the New York Stock Exchange (NYSE: DHR) as an S&P 500 Health Care component — developing, man
Regeneron Pharmaceuticals
Regeneron Pharmaceuticals, Inc. is a leading biotechnology company specializing in the discovery, development, and commercialization of medicines for serious diseases, headquartered in Tarrytown, New
Revvity
Revvity, Inc. (formerly PerkinElmer) is a global life science tools and diagnostics company, rebranded in 2023 to signal its transformation from a diversified instruments company into a focused provid
Compare Idexx Laboratories with Competitors
Side-by-side AI visibility scores, platform breakdown, and market position.
Claim This Profile
Are you from Idexx Laboratories? Claim your profile to see full AI mention excerpts, get weekly visibility change alerts, and optimize how AI systems describe your brand.
Claim Idexx Laboratories Profile →Track AI Visibility in Real Time
Monitor how ChatGPT, Gemini, Perplexity, and Claude mention Idexx Laboratories vs competitors. Get alerts when AI recommendations shift.
Start Free Tracking →